New formulation of combined action Levodopa We have started the evaluation of a new preparation of Levodopa, in capsules, with several wrapping layers, which allow a delay in the digestive release, an immediate effect and a later delayed effect. It would have the advantages of a Levodopa retard type Rytary, but with a combined effect of immediate action. It could improve motor fluctuations and the quality of life of patients.
Related Stories
8 de May de 2023
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
Posted in: Parkinson
8 de May de 2023
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
Posted in: Parkinson
22 de July de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
Posted in: Parkinson, Uncategorised
8 de April de 2020
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….
Posted in: Parkinson
2 de April de 2020
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….
Posted in: Parkinson
11 de March de 2020
Our Unit has achieved to be activated in this outstanding project and so serious pathology….
Posted in: Parkinson